| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SI |
| Uniprot No | P14410 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 全长 |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SI重组蛋白的3篇示例参考文献及摘要概括(内容为虚构示例，仅供参考)：
---
1. **文献名称**: *"High-yield Expression and Purification of SI Recombinant Protein in E. coli"*
**作者**: Zhang L, et al.
**摘要**: 研究通过优化大肠杆菌表达系统，实现了SI重组蛋白的高效可溶性表达，采用亲和层析技术纯化，获得高纯度蛋白，为后续功能研究奠定基础。
---
2. **文献名称**: *"SI Recombinant Protein Enhances Immune Response in Murine Models"*
**作者**: Smith J, et al.
**摘要**: 探讨SI重组蛋白作为免疫佐剂的潜力，实验显示其能显著增强小鼠模型中抗原特异性抗体水平，表明其在疫苗开发中的应用前景。
---
3. **文献名称**: *"Structural Analysis of SI Recombinant Protein via Cryo-EM"*
**作者**: Tanaka K, et al.
**摘要**: 利用冷冻电镜技术解析SI重组蛋白的三维结构，揭示其关键功能域构象，为靶向药物设计提供结构生物学依据。
---
4. **文献名称**: *"SI Recombinant Protein in Cancer Therapy: Mechanisms and Efficacy"*
**作者**: Wang Y, et al.
**摘要**: 研究SI重组蛋白通过调控肿瘤微环境抑制癌细胞增殖的分子机制，体外及体内实验证实其抗肿瘤活性，提示其作为新型治疗剂的潜力。
---
注：以上文献及作者为模拟示例，实际引用需检索PubMed、Google Scholar等平台获取真实数据。
**Background of SARS-CoV-2 Recombinant Spike (S) Protein**
Recombinant SARS-CoV-2 spike (S) protein, a key structural component of the virus, has been central to COVID-19 research and therapeutic development. The S protein mediates viral entry by binding to angiotensin-converting enzyme 2 (ACE2) receptors on host cells, making it a prime target for vaccines, therapeutics, and diagnostics. Recombinant S proteins are engineered using heterologous expression systems (e.g., mammalian, insect, or yeast cells) to mimic the native protein’s structure and function.
The development of recombinant S proteins accelerated during the pandemic, driven by their utility in subunit vaccines (e.g., Novavax’s NVX-CoV2373) and as antigens for serological assays. These proteins often include stabilizing mutations, such as proline substitutions (e.g., S-2P), to maintain prefusion conformation, enhancing immunogenicity. Additionally, recombinant S subunits (e.g., receptor-binding domain, RBD) are used in therapeutic antibody discovery and neutralization assays.
Challenges include ensuring proper post-translational modifications (e.g., glycosylation) for functional accuracy and scalability. Advances in expression systems, like CHO or HEK293 cells, have improved yield and quality. Beyond COVID-19. recombinant S protein research informs broader antiviral strategies, including pan-coronavirus vaccines. Ongoing efforts focus on optimizing stability, reducing production costs, and adapting to emerging variants. Overall, recombinant S proteins remain pivotal in combating SARS-CoV-2 and preparing for future pandemics.
×
